livtencity
(MARIBAVIR)Takeda Pharmaceuticals America, Inc.
Usage: LIVTENCITY is indicated for treating post-transplant cytomegalovirus (CMV) infection/disease in adults and pediatric patients (ages 12 and older, weighing at least 35 kg) that is refractory to prior treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet.